LTR Pharma

Aptar Pharma (NYSE: ATR) has highlighted use of its proprietary nasal delivery platform in LTR Pharma’s Phase II study of SPONTAN®, our intranasal therapy for the treatment of erectile dysfunction. Read the announcement: bit.ly/4rwvuxD

LTR Pharma has completed patient recruitment for its Phase II study of SPONTAN®. – an important step in the Company’s advances towards the US healthcare market. Read the ASX release: bit.ly/4aSJXyI $LTP #LTRPharma #erectiledysfunction  #clinicaltrial

$LTP releases Half Year Report (31 Dec 2025) • A$25.8m cash • Phase II approved & progressing • 1,000+ SPONTAN® SAS prescriptions • US SAB strengthened • ROXUS US launch preparations advancing Execution continues into 2H FY26. Full release: bit.ly/4sbfT7g

$LTP #LTRPharma #ErectileDysfunction #healthcare #sexualhealth #menshealth #nasalspray #PDE5

Positive outcomes reported with SPONTAN® in an independent case series of younger men with performance anxiety–related erectile difficulties. Read the ASX release: bit.ly/4t85UkB

$LTP #LTRPharma #ASX #menshealth #innovation #pharma #biotech #erectiledysfunction

$LTP | LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 December 2025 Read today’s ASX release here: bit.ly/4a1Bsjl

$LTP #LTRPharma #erectiledysfunction

LTR Pharma has announced that the first patients have been dosed in its Phase II pharmacokinetic clinical study of SPONTAN®, its rapid-acting intranasal spray for the treatment of erectile dysfunction. Read the ASX release: bit.ly/3LrbaPh

In case you missed it...LTR Pharma was featured in Tim Boreham's '2025's A-Z of biotechs' article in Stockhead, highlighting the Company's strengthening portfolio. Take a look: bit.ly/3NpeHxV $LTP #LTRPharma #biotech #nasalspray #innovation

#LTRPharma #erectiledysfunction

LTR Pharma has commenced patient recruitment for its Phase II study of SPONTAN®. The study includes a dedicated 65+ cohort to generate prescribing insights for older men, with initial data expected in Q2 CY2026. Read the ASX release: bit.ly/4pxGMAJ $LTP

$LTP #LTRPharma #WMSM2026 @ International Society for Sexual Medicine (ISSM)

Professor Eric Chung will deliver a podium presentation on LTR Pharma’s SPONTAN® Phase 1 study at the 2026 World Meeting on Sexual Medicine in Portugal next month. 🔗 Read the ASX release: bit.ly/3NxW9vo

LTR Pharma (ASX:LTP) has reached an important milestone with SPONTAN® - more than 1,000 prescriptions have now been issued in Australia through the TGA Special Access Scheme. 🔗Read the ASX release: bit.ly/48TcB0j

$LTP #SPONTAN #erectiledysfunction #clinicaltrial #menshealth

LTR Pharma has received regulatory clearance from the TGA for the commencement of the SPONTAN® Phase II clinical study, enabling formal initiation of clinical activities in Australia.  Read the ASX release: bit.ly/4oIwDR6

$LTP #LTRPharma #SPONTAN #clinicaltrials #menshealth

LTR Pharma has received ethics approval to commence the SPONTAN® Phase II pharmacokinetic and multiple-dose study, marking an important step in the Company’s FDA 505(b)(2) development pathway. Read the ASX release: bit.ly/4iSxEFb

Erectile dysfunction (ED) can be an early sign of heart disease, diabetes or hormonal imbalance. This #InternationalMensDay, we’re encouraging men to treat changes as a health signal. Talk to your GP, get checked! #MensHealth #EDAwareness #LTRPharma